Portal Hypertension Management
First-Line Management
- The American Association for the Study of Liver Diseases recommends non-selective beta-blockers (NSBBs) for variceal bleeding prophylaxis, and transjugular intrahepatic portosystemic shunt (TIPS) for refractory complications such as recurrent variceal bleeding and ascites 1, 2
- For primary prophylaxis of variceal hemorrhage, NSBBs are preferred over endoscopic band ligation (EBL) as they reduce portal pressure and prevent other complications of portal hypertension 1
- For secondary prophylaxis (prevention of rebleeding), combined therapy with NSBBs plus EBL is recommended as it significantly decreases rebleeding compared to monotherapy 1
- Acute variceal bleeding requires immediate administration of vasoactive agents (such as octreotide) followed by endoscopic therapy, with combination therapy improving 5-day hemostasis rates (77% vs 58% with endoscopy alone) 2
Advanced Management: TIPS
- TIPS is strongly recommended for gastro-esophageal variceal bleeding refractory to endoscopic and drug therapy 2
- Early or pre-emptive TIPS should be considered within 72 hours of a variceal bleed in high-risk patients (Child's C disease or MELD ≥19) 2
- TIPS is recommended for selected patients with refractory or recurrent ascites 2
- TIPS may be considered for hepatic hydrothorax, though further studies comparing it with standard of care are needed 3
- Contraindications for TIPS include bilirubin >50 μmol/L, platelets <75×10^9, pre-existing encephalopathy, active infection, severe cardiac failure, and severe pulmonary hypertension 2
- The presence of porto-pulmonary hypertension requires careful evaluation as TIPS may worsen pulmonary hypertension 4
Complications and Management
- Hepatic encephalopathy affects approximately one-third of patients after TIPS 2
- In most cases, hepatic encephalopathy responds to simple measures and medical therapy, but in severe cases, it may be necessary to reduce the diameter of or occlude the TIPS 3
- Patients with porto-pulmonary hypertension require supplemental oxygen to maintain arterial oxygen saturations >90% 4
- Cautious use of diuretics is recommended to control volume overload, edema, and ascites 4
- Anticoagulant therapy should be avoided in patients with impaired hepatic function, low platelet counts, or increased risk of bleeding due to gastroesophageal varices 4
Monitoring and Follow-up
- Hepatic venous pressure gradient (HVPG) measurement can guide therapy when available, with a target reduction to ≤12 mmHg or a ≥20% reduction from baseline 1
- Imaging studies such as Doppler ultrasound should be used to assess portal system patency after interventions 5
Portal Hypertension Management
Primary Pharmacological Options
- Non-selective beta-blockers (NSBBs) reduce portal pressure by decreasing cardiac output and causing splanchnic vasoconstriction, according to the World Journal of Emergency Surgery 6
- Octreotide, a somatostatin analog, reduces splanchnic blood flow, as reported by the World Journal of Emergency Surgery 6
- Terlipressin, a synthetic vasopressin analog, is more effective than octreotide with a longer half-life and fewer adverse effects, as stated by the World Journal of Emergency Surgery 6 and the Journal of the American College of Radiology 7
Stage-Specific Considerations
- In compensated cirrhosis with mild portal hypertension, NSBBs are mostly ineffective because the hyperdynamic circulatory state is not fully developed, as noted by Hepatology 8
- NSBBs are most effective in patients with clinically significant portal hypertension, where they prevent variceal development, decompensation, and death, according to Hepatology 8
Adjunctive Antibiotic Prophylaxis
- In cirrhotic patients with acute upper gastrointestinal bleeding from varices, short-course prophylactic antibiotics are strongly recommended, as they reduce mortality, bacterial infections, and rebleeding, as reported by the World Journal of Emergency Surgery 6
Initiating Propranolol in Portal Hypertensive Gastropathy
Clinical Context and Indication
- The Korean Association for the Study of the Liver (KASL) 2020 guidelines recommend nonselective beta-blockers for chronic bleeding from portal hypertensive gastropathy (PHG) in cirrhotic patients, with the goal of reducing iron-deficiency anemia and improving quality of life 9, 10
- Portal hypertensive gastropathy (PHG) causes chronic bleeding in cirrhotic patients, leading to iron-deficiency anemia and significantly reduced quality of life 9, 10
Specific Dosing Protocol
- The American Association for the Study of Liver Diseases (AASLD) and other guidelines suggest starting propranolol at 40 mg twice daily and titrating upward to 80 mg twice daily (or to maximal tolerated dose) with the goal of reducing resting heart rate by 25% or to 55 bpm, whichever is lower 11, 12
- Alternative: Long-acting propranolol 80 mg once daily can be used to improve compliance 11
Monitoring Parameters
- Baseline heart rate and blood pressure should be checked before initiation of propranolol, and monitored at each dose adjustment 13
- Assess severity of liver disease (Child-Pugh class) before initiating propranolol 11
Adjunctive Management
- The Korean Association for the Study of the Liver (KASL) recommends adding iron supplementation to address iron-deficiency anemia from chronic blood loss 9, 10
- For active bleeding episodes: Consider endoscopic argon plasma coagulation 9, 10
- For refractory cases: TIPS or other portal pressure-lowering interventions may be necessary 9, 10
Alternative if Propranolol Contraindicated
- If propranolol cannot be used due to contraindications or intolerance, nadolol is an acceptable alternative nonselective beta-blocker (NSBB) with similar efficacy, as suggested by the American Association for the Study of Liver Diseases (AASLD) 13
Management of Portal Hypertensive Gastropathy (PHG)
First‑Line Medical Management
- Initiate non‑selective beta‑blockers (e.g., propranolol or nadolol) together with iron supplementation for patients with chronic PHG‑related bleeding and anemia; reserve transjugular intra‑hepatic portosystemic shunt (TIPS) for those who remain transfusion‑dependent despite optimal medical therapy. [14][15]
- Start oral iron therapy in all PHG patients with iron‑deficiency anemia to restore iron stores. 15
- Switch to intravenous iron when oral iron is poorly tolerated, ferritin fails to rise after an adequate trial, or ongoing bleeding limits oral absorption. 15
- Prefer intravenous iron formulations that require only one to two infusions over regimens needing multiple administrations. 15
Differentiating PHG from Gastric Antral Vascular Ectasia (GAVE)
- Recognize that PHG and GAVE have distinct endoscopic appearances and require different treatments; accurate differentiation is essential. [16][14]
- GAVE is characterized by isolated red spots without a mosaic background, typically located in the gastric antrum and often arranged in a linear “watermelon” pattern. 16
- TIPS does not improve bleeding from isolated GAVE and should be avoided unless PHG co‑exists. [16][14]
- Endoscopic therapies (argon plasma coagulation, endoscopic band ligation, or radiofrequency ablation) are the primary treatment modalities for GAVE. [16][15]
Second‑Line Therapy: Transjugular Intra‑hepatic Portosystemic Shunt (TIPS)
- Consider TIPS in PHG patients who require repeated blood transfusions despite adequate NSBB therapy and iron repletion. [14][17]
- Indications for TIPS include:
- Transfusion‑dependent PHG refractory to NSBBs and iron supplementation. [16][14]
- Inability to tolerate or contraindications to NSBBs. 17
- TIPS has been shown to improve the endoscopic appearance of PHG lesions and to reduce transfusion requirements in refractory cases. 16
- Contraindications: a Child‑Pugh score greater than 13 (salvage TIPS not recommended). [16][14]
Monitoring and Follow‑Up
- Evaluate hemoglobin, ferritin, and transfusion needs every 2–3 months to gauge response to therapy. 15